Hepatic safety of caspofungin during treatment of fungal diseases in neonates  

卡泊芬净在新生儿真菌治疗中的肝脏安全性研究

作　　者：Gaole Yuan Yingqiu Tu Weiwei Yan Fang Wang 袁高乐;涂颖秋;晏伟伟;王芳(南昌大学第一附属医院,江西南昌330006)

机构地区：[1]The First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi,China

出　　处：《Journal of Chinese Pharmaceutical Sciences》2022年第11期877-882,共6页中国药学（英文版）

摘　　要：The use of caspofungin in neonates is beyond the instructions. Therefore, a retrospective analysis was performed to investigate the hepatic safety of caspofungin during the treatment of fungal diseases in neonates. A retrospective analysis was conducted on 23 neonates with Candida infection who were treated or prevented with caspofungin. Among the 23 neonates treated with caspofungin, 13 cases were cured(57%), and 10 cases showed improvements(43%). In addition, there were no adverse reactions associated with drug use, such as gastrointestinal tract, thrombocytopenia, and liver function damage. In summary, caspofungin achieved good results in the treatment or prevention of Candida infection in neonates, and no severe adverse reactions closely related to its use were found. However, the economy and safety of antifungal drugs should be considered in clinical practice for reasonable use.在新生儿中使用卡泊芬净属于超说明用药。因此,我们进行了一项针对卡泊芬净治疗或预防的23例新生儿念珠菌感染的回顾性研究,以调查卡泊芬净治疗新生儿真菌疾病期间的肝脏安全性。在接受卡泊芬净治疗的23例新生儿中,治愈13例(57%),好转10例(43%)。没有与药物使用相关的不良反应,如胃肠道、血小板减少和肝功能损害。总而言之,卡泊芬净治疗或预防新生儿念珠菌感染效果良好,未发现与使用密切相关的严重不良反应。但在临床实践中应考虑抗真菌药物的经济性和安全性,以便合理使用。

关 键 词：CASPOFUNGIN Candida infection NEONATE Liver function 

分 类 号：R969[医药卫生—药理学]